ABSTRACT

An HLA-A2 restricted tumor antigen peptide originated from SART-1, derivatives thereof having characteristics functionally equivalent thereto; therapeutic, prophylactic or diagnostic agents for tumors which utilize the tumor antigen peptide or its derivative, a recombinant DNA, recombinant polypeptide or antibody related to said tumor antigen peptide, or use thereof; an antigen presenting cell presenting the said tumor antigen peptide or use thereof; cytotoxic T lymphocyte specific for said tumor antigen peptide or use thereof.